Meta AnalysisID 680
榄香烯在接受化疗的癌症患者中的临床获益与风险：一项系统评价与Meta分析
CRD42022330190
Can elemene enhance the efficacy and reduce the adverse reactions of chemotherapy for cancer patients? Does elemene combined with chemotherapy have the effect of improving survival and quality of life of cancer patients?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 680
- Evidence Id
- 9238
- Core Evidence Id
- 9238
- Source Meta Analysis Id
- 659
- Herb2 Meta Analysis Id
- HBMA000659
- Crd Id
- CRD42022330190
- Title
- Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
- Review Question
- Can elemene enhance the efficacy and reduce the adverse reactions of chemotherapy for cancer patients? Does elemene combined with chemotherapy have the effect of improving survival and quality of life of cancer patients? What are the risks of using elemene for cancer patients undergoing chemotherapy? What types of cancer patients are suitable for elemene combined chemotherapy?
- Study Type Included
- Clinical studies including randomized controlled trials were included to assess the benefits and risks of the treatments.
- Condition Being Studied
- Cancer is one of the main factors threatening human health. The increasing incidence and mortality of cancer in China have brought serious challenges to cancer prevention and treatment. Chemotherapy is the main clinical treatment for cancer, but the bone marrow suppression and immune function damage reduce the quality of life of patients. Patients with advanced cancer are in poor overall condition and cannot tolerate standard doses of chemotherapy. Some patients have abnormal blood routines, especially leukopenia and thrombocytopenia. Some cancers, such as NSCLC, are insensitive to various anticancer drugs. Elemene is an anticancer active ingredient extracted from the ginger plant Wenyujin, which has effects on the proliferation, apoptosis and metastasis of cancer cells, and can improve the sensitivity of cancer cells to radiotherapy and chemotherapy. It is an ideal anticancer drug without myelosuppression and obvious liver and kidney toxicity. Elemene injection has been in clinical practice in China for more than 20 years and is used for the combined treatment of various cancers such as liver cancer andlung cancer. However, it has been reported that elemene may increase the risk of bleeding. The efficacy and safety of its combination with various chemotherapies for different cancers have not been systematically studied.
- Participant
- Inclusion: (1) Patients were diagnosed with cancer; (2) Clinical trials comparing two or more treatments, and the combination of elemene and chemotherapy compared with the same chemotherapy alone must be included; (3) The studies must have reported more than one of the following primary or secondary outcomes Exclusion: (1) Nonclinical studies; (2) Case reports, observational studies, systematic reviews, letters, editorials, clinical guidelines and commentaries; (3) lack of chemotherapy alone group; (4) Studies that did not report at least one of the following primary or secondary outcomes
- Animal
- Human Disease Modelled
- Intervention
- The experimental groups were treated with elemene combined with chemotherapy.
- Comparator Control
- Control groups: Patients who were treated with the same chemotherapy without elemene.
- Main Outcome
- The response rate, adverse effects, KPS score, quality of life improvement and stability rate, and the changes of immunocyte.
- Outcome Measure
- Additional Outcome
- The lung cancer symptom scale observer scale, the blood routine index, the serum cytokines levels, the disease control rate, the survival time/rate and tumor progression time.
- Study Method
- Systematic review
- Keyword
- Humans; Lung Neoplasms; Sesquiterpenes; elemene
- Contact
- Yanhong Pan [email protected]
- Organisational Affiliation
- The Second Affiliated Hospital of Nanjing Medical University
- Funding Source
- Science and technology development fundation of Nanjing Medical University is provided by Nanjing Medical University. Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> Science and technology development fundation of Nanjing Medical University, NMUB20210033, 2021-12-24
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-05-09
- Registration Date
- 2022-05-20
- Anticipated Start Date
- 2022-05-04
- Anticipated Completion Date
- 2022-06-07
- Title Cn
- 榄香烯在接受化疗的癌症患者中的临床获益与风险：一项系统评价与Meta分析
- Title En
- Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
- Bilingual Status
- complete